Ocaliva 5 Tablet

About Ocaliva 5 Tablet

Ocaliva 5 comes as a tablet with 5 mg of Obeticholic Acid, from Biopharma Ltd. Ask the doctor about what it is expected to do in your case.

There are 12 brands of Obeticholic Acid listed in Bangladesh. The lowest listed price is Bilovia 5 mg Tablet at ৳ 30.00 per unit.

What is Ocaliva 5 Tablet?

Ocaliva 5 is a tablet from Biopharma Ltd., with the generic name Obeticholic Acid. Doctors prescribe it for primary biliary cholangitis and some other cholestatic and fatty liver conditions. By acting on this receptor, it reduces the build-up of bile acids inside liver cells. The dose and course are set by the doctor.

Uses of Ocaliva 5

Ask the doctor about what it is expected to do in your case. Only a doctor can decide if this medicine is suitable. It is also used for some other cholestatic liver diseases and for non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH). Ask your doctor whether it is right for your condition.

How to use Ocaliva 5

The doctor may adjust the dose after checking blood tests and how well the medicine is tolerated. Ocaliva 5 is taken by mouth. Swallow the tablet with water. Take Ocaliva 5 5 mg tablet exactly as your doctor prescribes. Complete the course exactly as prescribed. The doctor decides the dose, how often to take it, and how long the course lasts.

Side effects of Ocaliva 5

Some people have liver-related problems, severe itching or a fall in a type of cholesterol, so the doctor checks for these. The doctor or pharmacist can advise on what to expect. Your doctor will advise on what to do. Tell your doctor promptly about itching, stomach problems or any unusual symptoms rather than stopping the medicine yourself.

Safety and precautions

Anyone with liver problems or other ongoing illness should speak to the doctor before starting. Ocaliva 5 must not be used by anyone allergic to Obeticholic Acid or any ingredient of the tablet, or by people with complete blockage of the bile ducts. Ask the doctor first if you have liver problems or take other medicines, including warfarin or bile acid binding resins. Keep out of reach of children.

Frequently asked questions

What does Ocaliva 5 treat?

Ask the doctor about what it is expected to do in your case. Only a doctor can decide if this medicine is suitable.

How is Ocaliva 5 used?

The doctor may adjust the dose after checking blood tests and how well the medicine is tolerated. Ocaliva 5 is taken by mouth.

What are the side effects of Ocaliva 5?

Some people have liver-related problems, severe itching or a fall in a type of cholesterol, so the doctor checks for these. The doctor or pharmacist can advise on what to expect.

Can I use Ocaliva 5 in pregnancy or while breastfeeding?

Anyone with liver problems or other ongoing illness should speak to the doctor before starting. Ocaliva 5 must not be used by anyone allergic to Obeticholic Acid or any ingredient of the tablet, or by people with complete blockage of the bile ducts.

Indications

Obeticholic Acid is indicated for the treatment of primary biliary cholangitis (PBC) in combination with Ursodeoxycholic Acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA, cholestatic liver disease & non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH).

Pharmacology

Obeticholic Acid is an agonist for FXR, a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic, and metabolic pathways. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing de novo synthesis from cholesterol as well as by increased transport of bile acids out of the hepatocytes. These mechanisms limit the overall size of the circulating bile acid pool while promoting choleresis, thus reducing hepatic exposure to bile acids.

Dosage & Administration

Starting Dosage: The recommended starting dosage of Obeticholic Acid is 5 mg orally once daily in adult patients who have not achieved an adequate biochemical response to an appropriate dosage of Ursodeoxycholic Acid (UDCA) for at least 1 year or are intolerant to UDCA.

Dosage Titration: If an adequate reduction in alkaline phosphatase (ALP) and/or total bilirubin has not been achieved after 3 months of Obeticholic Acid 5 mg once daily, and the patient is tolerating Obeticholic Acid, increase the dosage of Obeticholic Acid to 10 mg once daily.

Maximum Dosage: The maximum recommended dosage of Obeticholic Acid is 10 mg once daily.

Management of Patients with Intolerable Pruritus on Obeticholic Acid: For patients with intolerable pruritus on Obeticholic Acid, consider one or more of the following:

Add an antihistamine or bile acid binding resin. Reduce the dosage of Obeticholic Acid to:
  • 5 mg every other day, for patients intolerant to 5 mg once daily
  • 5 mg once daily, for patients intolerant to 10 mg once daily
Temporarily interrupt Obeticholic Acid dosing for up to 2 weeks followed by restarting at a reduced dosage

Increase the dosage of Obeticholic Acid to 10 mg once daily, as tolerated, to achieve optimal response. Consider discontinuing Obeticholic Acid treatment in patients who continue to experience persistent, intolerable pruritus.

Interaction

Bile Acid Binding Resins: Bile acid binding resins such as cholestyramine, colestipol, or colesevelam adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of Obeticholic Acid. If taking a bile acid binding resin, take Obeticholic Acid at least 4 hours before or 4 hours after taking the bile acid binding resin, or at as great an interval as possible.

Warfarin: The International Normalized Ratio (INR) decreased following co-administration of warfarin and Obeticholic Acid. Monitor INR and adjust the dosage of warfarin, as needed, to maintain the target INR range when co-administering Obeticholic Acid and warfarin.

CYP1A2 Substrates with Narrow Therapeutic Index: Obeticholic Acid may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index.

Contraindications

Contraindicated in patients known to have hypersensitivity to the drug or any of its components & in patients with complete biliary obstruction.

Side Effects

The most common side effects of Obeticholic Acid include: Pruritus, Fatigue & Stomach pain and discomfort. Other common side effects include rash, arthralgia (joint pain), oropharyngeal pain (pain in the middle part of the throat), dizziness, constipation, abnormal thyroid function, and eczema (inflammation of the skin).

Pregnancy & Lactation

The limited available human data on the use of Obeticholic Acid during pregnancy are not sufficient to inform a drug-associated risk.There is no information on the presence of Obeticholic Acid in human milk, the effects on the breast-fed infant or the effects on milk production.

Precautions & Warnings

The following clinically significant reactions are described:
  • Liver-Related Adverse Reactions
  • Severe Pruritus
  • Reduction in high density lipoprotein-cholesterol (HDL-C)
Special monitoring is essential for the patient with such type of problems

Overdose Effects

In PBC patients who received Obeticholic Acid 25 mg once daily (2.5 times the highestrecommended dosage) or 50 mg once daily (5 times the highest recommended dosage), a dose-dependent increase in the incidence of liver-related adverse reactions, including elevations in liver biochemical tests, ascites, jaundice, portal hypertension, and primary biliary cholangitis flare, was reported. In the case of over dosage, patients should be carefully observed and supportive care administered, as appropriate.

Storage Conditions

Store at 15°C to 30°C in a dry place protected from light. Keep out of reach of children

Alternative brands of Obeticholic Acid

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.